|

Empowering Mesothelioma Patients with Patient-Reported Symptom Monitoring

Empowering Mesothelioma Patients with Patient-Reported Symptom Monitoring

New data shows that patient-reported symptom monitoring improves the quality of life in lung cancer patients. The study was published in the Journal of the National Cancer Institute.

Enhancing Life Quality for Lung Cancer Patients

Pleural mesothelioma is an asbestos-related cancer that affects the lungs. Mesothelioma patients have many of the same symptoms as lung cancer patients. Among other things, they tend to suffer from breathing problems, chest pain, cough, weakness, and fatigue.

One recent study focused on how patients’ lives can be improved during and after lung cancer treatment. Researchers were interested in using “patient-reported outcomes measures.” Or PROMs for short. PROMS can monitor how patients are feeling. These PROMs would help keep track of symptoms and make sure that patients were getting the best care possible.

In the past, these PROMs were sent to clinicians, who would decide what to do based on the information. But in this new study, the researchers wanted to see if it would work better to send alerts directly to the patients themselves. This way, patients could be more involved in their own care and treatment.

The main goal of the study was to compare two different ways of using these alerts. In the first way, patients would get an alert if something seemed wrong. This is called the “reactive approach”. In the second way, the clinician would get an alert and then let the patient know what to do. This is called the “active approach”. Researchers wanted to see which approach was better at improving the patient’s quality of life.

Reactive vs. Active: The New Frontier in Mesothelioma Care

What they found was that patients who got alerts directly seemed to benefit just as much as those who had their healthcare providers get the alerts. The “reactive approach” benefited just as much as the “active approach.” This means that patients can play a bigger role in their own care, and this could be a simpler way to make sure they’re feeling their best.

In summary, this study shows that paying attention to symptoms and using alerts can really make a difference for lung cancer patients. It’s like having a little extra help to make sure everything is going well. And what’s even better is that patients can get this help directly, which might be easier for everyone.

Researchers are always finding new ways to improve mesothelioma care. Studies like this one are a big step in the right direction.

Source

Billingy, N. E., N M F Tromp, V., Aaronson, N. K., Hoek, R. J. A., Bogaard, H. J., Onwuteaka-Philipsen, B. D., van de Poll-Franse, L., Hugtenburg, J. G., Belderbos, J., Becker-Commissaris, A., van den Hurk, C. J. G., Walraven, I., & the SYMPRO-Lung Consortium. (2023). Quality of life after patient-initiated versus physician-initiated response to symptom monitoring: The SYMPRO-Lung trial. JNCI: Journal of the National Cancer Institute, djad159. https://doi.org/10.1093/jnci/djad159

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…

  • | |

    Value of Mesothelioma Surgery Challenged for Healthy Patients

    New research conducted in Italy and presented at the 15th World Conference on Lung Cancer in Sydney, Australia suggests that mesothelioma surgery – no matter what kind – may not offer a survival advantage over medical management for the healthiest of patients. Mesothelioma is a rare but aggressive malignancy that is highly resistant to standard cancer treatments. The two types of mesothelioma surgery considered to be options for people with resectable cancer are pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP). While EPP is more radical than P/D because it involves removing a lung, both carry a heavy risk of complications and, according to the Italian researchers, may not be of value for certain patients. The study reviewed data from 1,365…